Novartis added inclisiran to its pipeline after buying The Medicines Company – which had licensed the drug from Alnylam – for $9.7 billion in 2019, and will be hoping for a swift uptake in the ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

GP collective action in Kent has led to an agreement from the ICB to fund new locally-commissioned services, including for ...

Repatha and Praluent are also facing the threat of competition from inclisiran, an RNAI interference drug originally developed by The Medicines Company that only needs to be delivered by injection ...

每天吃药、定期复查，血脂还是居高不下？高血脂，这一心脑血管疾病的「隐形杀手」，每年导致全球近400万人死亡。 而近期，《Nature ...

Allergan was running a long-term study on silicone breast implants. I had always wanted a more feminine body like the girls in the magazines, so I joined and got implants. They never followed up with ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...

阿里拉姆制药现在的股价报241.76 阿里拉姆制药的股票在哪间交易所挂牌交易？ 阿里拉姆制药的股票在纳斯达克挂牌交易。 阿里拉姆制药的股票代码是什么？ 阿里拉姆制药的股票代码是“ALNY。” 阿里拉姆制药的市值是多少？ 截至今天，阿里拉姆制药的市值是31 ...